Efficacy and safety results of the early phse studies with exel™ (ENA-713) in alzeimer's disease: An overview

Journal of Drug Development and Clinical Practice

Volumn 8, Issue 2, 1996, Pages 109-116

  Anand, R ^a  

^a NONE

Author keywords

Alzheimer's disease; Clinical trial; Efficacy; ENA 713

Indexed keywords

CHOLINESTERASE INHIBITOR; RIVASTIGMINE;

ALZHEIMER DISEASE; BRAIN CORTEX; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MEMORY; META ANALYSIS; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOMETRY; REVIEW; VERTIGO;

EID: 0029766994     PISSN: 13579215     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Davies P, Maloney AJE Lancet 1976;ii:1403.
2. Sims NR, Smith CCT, Davison AM, et al. Lancet 1980;i:333-335.
3. Whitehouse PJ. Price DL, Struble RG, et al. Science 1982;215:1237-1239.
4. Becker RE. Therapy of the cognitive deficit in Alzheimers disease: The cholinergic system. In:
5. Becker RE, Giacobini E, editors. Cholinergic basis for Alzheimer therapy. Boston: Birkhâuser, 1991: 1-22.
6. Enz A, Amstutz R, Boddeke H, et al. Prog Brain Res 1993; 98:431-438.
7. Kennedy JS, Polinsky RJ, Johnson B et al. Preferential central nervous system acetylcholinesterase inhibition by SDZ ENA-713 in man. Poster presented at American Collegium Keuropsychopharmacologicum meeting, San Juan, Puerto Rico, December 1995.
8. Agid Y and the Exelon'M Study Group. A multicentered, placebo-controlled study on the efficacy and tolerability of SDZ ENA-713 in patients with mild-moderate dementia of the Alzheimer type. (In preparation)
9. National Institutes for Mental Health: 028 CGIC. Clinical Global Impressions. In: Guy \V, editor. ECDEU Assessment manual for psychopharmacology. Rockville, Maryland: NIMH, 1976:207-212.
10. Fuld PA. The Fuld object memory evaluation. Chicago: Steelling Instrument Co., 1981.
11. Weschler D. Manual for the Wechsler Adult Intelligence Scale. New York: Psychological Corporation, 1995.
12. Benton AL. Revised visual retention test. 4th edition. San Antonio, Texas: The Psychological Corporation, 1974.
13. Reitan RM. Percept Mot Skills 1958;8:271-276.
14. Rosen W, Mohs R, Davis K. Am J Psychiatry 19S4;141:1356-1364.
15. Wechsler D. Wechsler Memory Scale - Revised Manual. The Psychological Corporation. San Antonio, Texas: Harcoun Brace Jovanovich Inc. 19S7.
16. Wechsler D. Manual for the Wechsler Adult Intelligence Scale. New York: The Psychological Corporation, 1955.
17. Sramek JJ, Anand R, Wardle TS, et al. Safety/tolerability trial of SDZ ENA-713 in patients with probably Alzheimer's disease. Life Sci 1996;58:1201-1207.
18. Anand R, Gharabawi G. The ADENA programme: International coordinated phase III development of a second generation acetylcholinesterase inhibitor (SDZ ENA-713). Poster presented at the Lancet Conference, The Challenge of the Dementias', Edinburgh, April 25-26, 1996.